Hafrun Fridriksdottir — Executive Vice President of Global R&D at Teva Pharmaceutical Industries Limited

Dr. Hafrun Fridriksdottir, Ph.D., has been Executive Vice President of Global R&D at Teva Pharmaceutical Industries Limited since November 27, 2017. Dr. Fridriksdottir served as Executive Vice President at Teva Pharmaceutical Industries Limited since February 2017 until November 27, 2017 and served as its President of Global Generics R&D since 2016 until November 27, 2017. Prior to joining Teva, from 2015 to 2016, Dr. Fridriksdottir served as Senior Vice President and President of Global Generics R&D in Allergan plc (formerly, Actavis plc; Watson Pharmaceuticals, Inc.). From 2002 to 2015, she held positions of increasing responsibility within the Actavis Group, including Senior Vice President, R&D. Dr. Fridriksdottir served as Vice President of Research & Development at Actavis, Inc. (formerly Actavis LLC). From 1997 to 2002, she served as Divisional Manager of Development at Omega Pharma, until its merger with Actavis. Dr. Fridriksdottir received an MS degree in pharmacy and a Ph.D. in physical pharmacy from the University of Iceland.